Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline
Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.
You may also be interested in...
With sales of its largest-selling product under threat from generic competition, a couple of new products and cost cuts are put forward to reinvigorate Indivior, a leader in addiction therapies.
Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.
Having had to retrench after a financial crisis four years ago, Swiss biotech Addex Therapeutics has been focusing on its in-house platform around allosteric modulation. CEO Tim Dyer speaks to Scrip in a video interview recorded at Biotech Showcase.